BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15330202)

  • 1. Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer.
    Uno T; Isobe K; Kawakami H; Ueno N; Kobayashi H; Shimada H; Mastubara H; Okazumi S; Nabeya Y; Shiratori T; Ochiai T; Kawata T; Ito H
    Anticancer Res; 2004; 24(4):2483-6. PubMed ID: 15330202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoradiation for patients with esophageal cancer aged 80 and older.
    Uno T; Kawakami H; Funami Y; Isobe K; Yasuda S; Aruga T; Shimada H; Okazumi S; Nabeya Y; Mastubara H; Ochiai T; Ito H
    Anticancer Res; 2001; 21(6A):4095-7. PubMed ID: 11911299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoradiation for esophageal cancer: institutional experience with three different regimens.
    Courrech Staal EF; Aleman BM; van Velthuysen ML; Cats A; Boot H; Jansen EP; van Coevorden F; van Sandick JW
    Am J Clin Oncol; 2011 Aug; 34(4):343-9. PubMed ID: 20562589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
    Seung SK; Smith JW; Molendyk J; Bader SB; Phillips M; Regan J; Louie J; Soo E; Seligman M; Ruzich J; Skokan L; Ross HJ
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):13-9. PubMed ID: 15726517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term results of chemoradiation therapy for the patients with locally advanced (T4) esophageal cancer].
    Sekikawa K; Onogi H; Yazawa T; Sato Y; Sakamoto W; Miyamoto K; Fujita S; Suzuki S; Endo Y; Ohki S; Takenoshita S
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1253-6. PubMed ID: 16969020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
    Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
    Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
    Brunner TB; Rupp A; Melzner W; Grabenbauer GG; Sauer R
    Strahlenther Onkol; 2008 Jan; 184(1):15-22. PubMed ID: 18188518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of complete response to esophageal cancer by a novel concurrent chemoradiation therapy.
    Shimoyama S; Aoki F; Kojima J; Kaminishi M
    Hepatogastroenterology; 1999; 46(28):2409-13. PubMed ID: 10522007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
    Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas.
    Kawakami H; Uno T; Isobe K; Ueno N; Aruga T; Sudo K; Yamaguchi T; Saisho H; Kawata T; Ito H
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1357-62. PubMed ID: 16029793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy.
    Chauveinc L; Buthaud X; Falcou MC; Mosseri V; De la Rochefordière A; Pierga JY; Girodet J; Salmon RJ
    Br J Cancer; 2003 Dec; 89(11):2057-61. PubMed ID: 14647138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
    Maurel J; Cervantes A; Conill C; Salazar R; Martin-Richard M; Pera M; Manzano H; Chirivella I; Gallego R; Marfa X
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):91-6. PubMed ID: 15850907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of 5-fluorouracil, leukovorin, etoposide, and cisplatin (FLEP) in patients with metastatic esophageal cancer. A single-institution experience.
    Jonak C; Raderer M; Zacherl J; Prager G; Troch M; Ba-Ssalamah A; Hejna M
    Anticancer Res; 2008; 28(6B):4101-4. PubMed ID: 19192667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer].
    Iwase H
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():224-9. PubMed ID: 16898007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.
    Zhang Z; Liao Z; Jin J; Ajani J; Chang JY; Jeter M; Guerrero T; Stevens CW; Swisher S; Ho L; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):656-64. PubMed ID: 15708243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
    Morota M; Gomi K; Kozuka T; Chin K; Matsuura M; Oguchi M; Ito H; Yamashita T
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):122-8. PubMed ID: 19327900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.